Leeds, UK, April 19, 2021 - 4D pharma plc (AIM: DDDD; NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces a collaboration with Parkinson s UK, a non-profit organization focused on advancing the understanding of Parkinson s disease and improving treatments, to establish a Patient Advisory Board.
The Patient Advisory Board (PAB) will be comprised of people living with Parkinson s. Supported by Parkinson s UK, the PAB will provide valuable patient-centric perspective to 4D pharma as it continues to advance novel Live Biotherapeutics into the clinic to treat neurodegenerative conditions such as Parkinson s. The PAB will also focus on raising awareness of the issues people with Parkinson s face with current treatment options.
GT Biopharma Reports Fourth Quarter and Year End 2020 Results and Business Update
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Investegate |4d Pharma PLC Announcements | 4d Pharma PLC: Directors Subscription for new Ordinary Shares
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.